Acrivon Therapeutics, Inc. (ACRV)
Develops cancer drugs matched to patients using protein analysis to predict which tumors will respond.
$1.54-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+22.2%
The outlook
ACRV is trading well below its recent moving averages and sits near the lower end of its 52-week range. Analyst sentiment leans bearish overall, though the average price target sits significantly above the current price. The stock shows weak momentum in its near-term trend.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range14% of the way from its 52-week low to high
Price targetAvg target +647% vs current price
Analyst price target
~12-month · 6 analysts$11.50average target+646.8% vs now
Now $1.54
Low $7.00High $19.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$65.9M
52-wk high
$3.56
52-wk low
$1.20
50-day avg
$1.67
200-day avg
$1.87
Trailing P/E
—